Dr. Reddy’s sets SBTi-approved Net Zero target for FY2045
The company outlines near-term and long-term emission reduction goals across its value chain
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s
Dr. Reddy’s receives positive CHMP opinion from EMA for AVT03
Dr. Reddy’s Laboratories announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
Dr. Reddy’s launches Tegoprazan in India
Dr. Reddy’s Laboratories announced the launch of the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in…
Dr. Reddy’s acquires STUGERON to strengthen its CNS portfolio
Dr. Reddy’s, a global pharmaceutical company has announced the completion of a definitive transaction with Johnson & Johnson,…
Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise…
Dr Reddy’s Laboratories, Emcure Pharma, Hetero Drugs and Mylan Labs (a subsidiary of Viatris), are among the six companies that…
Dr Reddy’s receives positive CHMP opinion for biosimilar Rituximab candidate in European markets
Dr Reddy's Rituximab biosimilar DRL_RI (ITUXREDI) progresses towards European approval with EMA CHMP endorsement
Alvotech and Dr Reddy’s collaborate on biosimilar AVT03
Dr Reddy’s gets exclusive commercialisation rights of denosumab in the US as well as semi-exclusive rights in Europe and UK
Industry growth weakens sharply in Mar’24
For the 12 months through Mar’24, IPM grew 7.6 per cent YoY and prices/volume/new launches increased by 4.0 per cent/0.7 per…
Dr Reddy’s rolls out Nerivio, drug-free non-invasive migraine management device, in India
Nerivio is the first and only USFDA approved device to use Remote Electrical Neuromodulation (REN) to prevent and treat migraine
USFDA completes GMP inspection of Dr Reddy’s Hyderabad API manufacturing facility
The inspection closed with zero observations